A phase 1 dose-escalation and expansion study of CUE-101, given as monotherapy in 3rd line and in combination with pembrolizumab in 1st line recurrent/metastatic (R/M) HPV16+ head and neck cancer patients Meeting Abstract
| Authors: | Colevas, A. D.; Chung, C. H.; Adkins, D.; Rodriguez, C. P.; Park, J. C.; Gibson, M. K.; Sukari, A.; Burtness, B.; Johnson, F. M.; Julian, R. A.; Saba, N. F.; Worden, F.; Dunn, L.; Seiwert, T. Y.; Jotte, R. M.; Haddad, R.; Gabrail, N.; Bauman, J.; Margossian, S. P.; Pai, S. I. |
| Abstract Title: | A phase 1 dose-escalation and expansion study of CUE-101, given as monotherapy in 3rd line and in combination with pembrolizumab in 1st line recurrent/metastatic (R/M) HPV16+ head and neck cancer patients |
| Meeting Title: | 2024 Multidisciplinary Head and Neck Cancers Symposium |
| Journal Title: | International Journal of Radiation Oncology, Biology, Physics |
| Volume: | 118 |
| Issue: | 5 |
| Meeting Dates: | 2024 Feb 29-Mar 2 |
| Meeting Location: | Phoenix, AZ |
| ISSN: | 0360-3016 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2024-04-01 |
| Start Page: | e87 |
| Language: | English |
| DOI: | 10.1016/j.ijrobp.2024.01.192 |
| PROVIDER: | EBSCOhost |
| PROVIDER: | cinahl plus with full text |
| DOI/URL: | |
| Notes: | Meeting Abstract: 257 -- Accession Number: 175934857 -- Entry Date: In Process -- Revision Date: 20240313 -- Publication Type: Journal Article -- Journal Subset: Biomedical; Peer Reviewed; USA -- NLM UID: 7603616. -- Source: CINAHL Plus with Full Text |
